Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study

Bristol-Myers Squibb Co. (BMY) said its experimental hepatitis C compounds, protease inhibitor asunaprevir combined with its NS5A inhibitor daclatasvir, cured 77 percent of difficult-to-treat patients 24 weeks after treatment ended, according to a mid-stage study.

Difficult-to-treat patients included those who didn’t respond to prior therapy and patients who were medically ineligible or intolerant to previous treatment, the company said in a statement today.

In a separate mid-stage study, Bristol-Myers’ experimental peginterferon lambda drug had a cure rate similar to peginterferon alfa with fewer side effects, the company said.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.